Open access · US-GOV
via ClinicalTrials.gov Clinical trial
The Mechanism Study of Diabetic Pancreatic Amyloid Deposition on Cognitive
Authors not listed
Huashan Hospital · 2021
Abstract
Alzheimer's disease (AD) is closely related to diabetes (DM). DM will aggravate the progression of AD, but the specific mechanism has not yet been clarified. Previous study found that a key pathological feature of the pancreas in patients with DM is islet amyloid polypeptide, and there is also islet amyloid polypeptide in the brain. Therefore, DM may cause cytotoxicity through the interaction between pancreatic amyloid and brain Aβ protein and further aggravate AD progress. In this study, starting with DM and AD pathological biomarkers, the amyloid PET target molecular probe 18F-AV45 will be used to monitor the dynamic changes of amyloid protein in the brain and pancreas during the development of AD. The completion of this study will provide a new view for understanding the mechanism of DM on AD cognitive dysfunction and effectively preventing and treating these two diseases.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-10 MST
Cite this
APA
Anonymous. (2021). The Mechanism Study of Diabetic Pancreatic Amyloid Deposition on Cognitive. <em>Huashan Hospital</em>. https://clinicaltrials.gov/study/NCT05372458
Vancouver
Anonymous. The Mechanism Study of Diabetic Pancreatic Amyloid Deposition on Cognitive. Huashan Hospital. 2021.
BibTeX
@misc{anon2021TheMec,
title = {The Mechanism Study of Diabetic Pancreatic Amyloid Deposition on Cognitive},
author = {Anonymous},
journal = {Huashan Hospital},
year = {2021},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Aaron Ritter, MD 2018
Open access · US-GOV
The Relationship Between Neuropsychological Testing and MRI, PET and Blood Biomarkers in Neurodegenerative Disease (COBRE - Project 1): AIM 2
Optina Diagnostics Inc. 2022
Open access · US-GOV
Evaluation of Optina Retina Scans to Detect the Likeley Cerebral Amyloid Status (CAS) as Determined by Prospective PET Imaging
University of Pennsylvania 2017
Open access · US-GOV
Tau PET Imaging in the NACC Study Cohort: Modulators of MTL Subregion Structure and Function in Normal and Pathological Aging
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation 2018
Open access · US-GOV
AlfaAge: Cross-sectional Study for the Identification of Blood Biomarkers in Healthy Young and Old Individuals
National Eye Institute (NEI) 2008
Open access · US-GOV
Pilot Study for the Detection of Neutralizing Antibodies in Patients Treated With Bevacizumab Avastin or Ranibizumab Lucentis
University of Colorado, Denver 2016
Open access · US-GOV